Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2013 Nov 1;2(11):e26587. Epub 2013 Oct 10.

Boosting leukemia-specific T cell responses in patients following stem cell transplantation.

Author information

1
Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA.
2
Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA ; Department of Medicine; Brigham and Women's Hospital; Harvard Medical School; Boston, MA USA.

Abstract

Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation stand out as a promising approach to enhance graft-vs.-leukemia responses. Herein, the implications of this finding for the development of strategies to improve the outcome of patients subjected to allogeneic stem cell transplantation are discussed.

KEYWORDS:

CLL; cancer vaccines; immune reconstitution; multiepitope vaccines; neoantigens; stem cell transplantation; whole tumor-cell vaccination

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center